目的:评价地塞米松联合曲安奈德(TA)在白内障超声乳化人工晶状体植入术后的临床效果。
方法:发布,Embase,并在Cochrane图书馆搜索了截至2020年8月发表的研究。主要结果是眼内压。次要结果是最小分辨率角(logMAR)的对数,前房细胞,和前房耀斑。合并效应大小表示为95%置信区间(95%CIs)的加权平均差(WMD)或标准化平均差(SMD)。Cochrane协作偏倚风险工具和纽卡斯尔-渥太华量表标准用于纳入研究的质量评估。
结果:7项相关研究符合纳入标准。对于主要结果,TA注射和地塞米松在比较眼内压(IOP)方面没有显着差异(SMD=0.22,95%置信区间[CI][-0.29,0.73],P=.408;I²=86.9%)在治疗后的第一天和评估的最后一天。对于次要结果,logMAR(WMD=0.01,95%CI[-0.06,0.08])和前房耀斑(SMD=0.08,95%CI[-0.01,0.18],P=.087;I²=0%)显示无差异。然而,前房细胞数量(SMD=-0.21,95%CI[-0.42,-0.01],P=.044;I²=0%)术后第一天的TA注射高于地塞米松。治疗后,两组间无差异。
结论:这项研究支持眼压没有差异,logmar,白内障患者中TA注射和地塞米松之间的前房耀斑。第一天的TA注射治疗显示前房细胞量高于地塞米松。
OBJECTIVE: To evaluate the clinical effects between dexamethasone and triamcinolone acetonide (TA) after phacoemulsification and intraocular lens implantation among cataract patients.
METHODS: Pubmed, Embase, and the Cochrane Library were searched for studies published up to August 2020. The primary outcome was intraocular pressure. The secondary outcomes were the logarithm of the minimum angle of resolution (logMAR), anterior chamber cell, and anterior chamber flare. The pooled effect sizes were expressed as weighted mean differences (WMDs) or standardized mean differences (SMDs) of 95% confidence intervals (95% CIs). Cochrane Collaboration risk of bias tool and Newcastle-Ottawa scale criteria were used for the quality assessment of included studies.
RESULTS: Seven relevant studies met the inclusion criteria. For the primary outcome, there was no significant difference between TA injection and dexamethasone in comparing intraocular pressure (IOP) (SMD = 0.22, 95% confidence interval [CI] [-0.29, 0.73], P = .408; I² = 86.9%) in the first day after treatment and last day of assessment. For the secondary outcomes, the logMAR (WMD = 0.01, 95% CI [-0.06, 0.08]) and the anterior chamber flare (SMD = 0.08, 95% CI [-0.01, 0.18], P = .087; I² = 0%) showed no differences. However, the amount of anterior chamber cells (SMD = -0.21, 95% CI [-0.42, -0.01], P = .044; I² = 0%) in the TA injection on the first day postoperative was higher than for dexamethasone. After treatment, there was no difference between the 2 groups.
CONCLUSIONS: This study supports that there were no differences in IOP, logMAR, and anterior chamber flare between TA injection and dexamethasone among cataract patients. TA injection treatment on the first day showed higher amounts of anterior chamber cells than with dexamethasone.